Total Payments
$5,849
2024 Payments
$5,323
Companies
9
Transactions
20
Medicare Patients
15
Medicare Billing
$6,468

Payment Breakdown by Category

Consulting$4,671 (79.9%)
Food & Beverage$1,046 (17.9%)
Education$131.98 (2.3%)

Payments by Nature

Nature of Payment Amount Transactions Share
Consulting Fee $4,671 2 79.9%
Food and Beverage $1,046 16 17.9%
Education $131.98 2 2.3%

Top Paying Companies

Company Total Records Latest Year
Janssen Global Services, LLC $4,671 2 $0 (2024)
Seagen Inc. $381.98 4 $0 (2023)
PFIZER INC. $160.76 3 $0 (2024)
GENZYME CORPORATION $140.51 2 $0 (2024)
Current Health Inc. $139.17 2 $0 (2024)
Amgen Inc. $122.11 1 $0 (2022)
Janssen Biotech, Inc. $106.32 2 $0 (2024)
Janssen Scientific Affairs, LLC $66.72 3 $0 (2024)
AstraZeneca UK Limited $60.00 1 $0 (2024)

Payment History by Year

Year Amount Transactions Top Company
2024 $5,323 14 Janssen Global Services, LLC ($4,671)
2023 $153.66 3 Seagen Inc. ($131.98)
2022 $122.11 1 Amgen Inc. ($122.11)
2021 $250.00 2 Seagen Inc. ($250.00)

All Payment Transactions

20 individual payment records from CMS Open Payments

Date Company Product Nature Form Amount Type
12/09/2024 Janssen Global Services, LLC TECVAYLI (Biological) Consulting Fee Cash or cash equivalent $1,350.00 General
Category: Oncology
12/08/2024 PFIZER INC. ELREXFIO (Drug), ADCETRIS Food and Beverage In-kind items and services $23.96 General
Category: ONCOLOGY
12/07/2024 Janssen Biotech, Inc. DARZALEX (Biological) Food and Beverage In-kind items and services $67.29 General
Category: Oncology
12/07/2024 AstraZeneca UK Limited Food and Beverage In-kind items and services $60.00 General
11/12/2024 Janssen Global Services, LLC TECVAYLI (Biological) Consulting Fee Cash or cash equivalent $3,321.00 General
Category: Oncology
10/01/2024 Current Health Inc. Food and Beverage Cash or cash equivalent $48.28 General
09/28/2024 Janssen Biotech, Inc. CARVYKTI (Drug) Food and Beverage In-kind items and services $39.03 General
Category: Oncology
09/26/2024 PFIZER INC. ELREXFIO (Drug) Food and Beverage In-kind items and services $18.45 General
Category: ONCOLOGY
08/03/2024 Current Health Inc. Food and Beverage Cash or cash equivalent $90.89 General
07/17/2024 Janssen Scientific Affairs, LLC TECVAYLI (Biological), TALVEY, DARZALEX Food and Beverage In-kind items and services $29.76 General
Category: Oncology
07/16/2024 Janssen Scientific Affairs, LLC DARZALEX (Biological), TALVEY, TECVAYLI Food and Beverage In-kind items and services $15.28 General
Category: Oncology
06/02/2024 PFIZER INC. ELREXFIO (Drug), ADCETRIS Food and Beverage In-kind items and services $118.35 General
Category: ONCOLOGY
05/13/2024 GENZYME CORPORATION SARCLISA (Biological) Food and Beverage In-kind items and services $118.17 General
Category: Oncology
01/17/2024 GENZYME CORPORATION SARCLISA (Biological) Food and Beverage In-kind items and services $22.34 General
Category: Oncology
09/29/2023 Janssen Scientific Affairs, LLC DARZALEX (Biological) Food and Beverage In-kind items and services $21.68 General
Category: Oncology
06/06/2023 Seagen Inc. Education In-kind items and services $61.99 General
02/07/2023 Seagen Inc. Education In-kind items and services $69.99 General
04/07/2022 Amgen Inc. LUMAKRAS (Drug) Food and Beverage In-kind items and services $122.11 General
Category: Oncology
11/03/2021 Seagen Inc. ADCETRIS (Biological) Food and Beverage In-kind items and services $125.00 General
Category: Oncology
10/21/2021 Seagen Inc. ADCETRIS (Biological) Food and Beverage In-kind items and services $125.00 General
Category: Oncology

Medicare Billing by Year

Year Procedures Beneficiaries Services Submitted Medicare Paid
2023 1 15 61 $31,720 $6,468
Total Patients
15
Total Services
61
Medicare Billing
$6,468
Procedure Codes
1

All Medicare Procedures & Services

1 procedure records from CMS Medicare Utilization

HCPCS Description Setting Year Patients Services Charges Medicare Paid Ratio
99233 Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes Facility 2023 15 61 $31,720 $6,468 20.4%

About Dr. Sridevi Rajeeve, MD

Dr. Sridevi Rajeeve, MD is a Student in an Organized Health Care Education/Training Program healthcare provider based in New York, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/13/2017. The National Provider Identifier (NPI) number assigned to this provider is 1154843944.

According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Sridevi Rajeeve, MD has received a total of $5,849 in payments from pharmaceutical and medical device companies, with $5,323 received in 2024. These payments were reported across 20 transactions from 9 companies. The most common payment nature is "Consulting Fee" ($4,671).

As a Medicare-enrolled provider, Rajeeve has provided services to 15 Medicare beneficiaries, totaling 61 services with total Medicare billing of $6,468. Data is available for 1 year (2023–2023), covering 1 distinct procedure/service records.

Practice Information

Products in Payments

  • TECVAYLI (Biological) $4,701
  • ADCETRIS (Biological) $250.00
  • ELREXFIO (Drug) $160.76
  • SARCLISA (Biological) $140.51
  • LUMAKRAS (Drug) $122.11
  • DARZALEX (Biological) $104.25
  • CARVYKTI (Drug) $39.03

Data Sources

Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.

Student in an Organized Health Care Education/Training Program Doctors in New York